在头癌治疗中,2,2'-二二二胺酸衍生物的抗癌潜力
Manasa Gangadhar Shetty1, Bipasa Dey1, Padmini Pai1
1Department of Biophysics, Manipal School of Life Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Journal of computer-aided molecular design
|August 6, 2025
概括
一种新型的基尿素衍生物,化合物1A,在头癌 (HNC) 治疗中表现有前途. 它选择性地杀死癌细胞,抑制迁移,并诱导细胞亡,提供了潜在的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 癌症生物学 癌症生物学
背景情况:
- 由于毒性和耐药性,头癌 (HNC) 治疗面临着当前化疗的挑战.
- 作为一种抗癌剂的素尿素具有局限性,包括短半衰期和毒性.
- 开发具有改进性质的新衍生物对于有效的HNC治疗至关重要.
研究的目的:
- 设计和合成用于HNC处理的新型2,2'-二二氨酸胺酸衍生物,包括氧尿素类似物.
- 评估这些新化合物的化疗疗效果和安全性.
- 调查有前途的候选人的作用机制.
主要方法:
- 合成两种新型的2,2-二二氨酸胺酸衍生物.
- 对 Cal27 HNC 细胞的选择性细胞毒性的评估.
- 机理学研究包括细胞迁移试验,反应性氧物种 (ROS) 检测和亡试验.
- 基因组脱乙酶 (HDAC) 抑制试验,分子对接和分子动力学模拟.
主要成果:
- 化合物1A是一种基尿素模拟物,对Cal27细胞具有选择性细胞毒性 (IC50 = 19.36μM).
- 化合物1A证明抑制了癌细胞迁移,并诱导了ROS介导的亡.
- 化合物1A显示了中度的HDAC抑制,并通过模拟证实了稳定地与HDAC2异型结合.
结论:
- 化合物1A是治疗头癌症的有希望的主要候选者.
- 该化合物结合了表观遗传调节 (HDAC抑制) 与直接细胞毒性作用.
- 进一步开发化合物1A可能会导致改善HNC化疗策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
444
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
444
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
260
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
260
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K


